Claybrook Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Claybrook Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-221	Closed	-$22K	–	756
2018 Q4	$22K	Buy	+221	New	+$26.1K	0.01%	344

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Claybrook Capital's ALXN Position: Q1 2019 in Review

Claybrook Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 221 shares — an estimated $22K sold.

Claybrook Capital first reported a position in ALXN in Q4 2018 and held it in 1 quarter. The position peaked at $22K in Q4 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

Claybrook Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Claybrook Capital sold 221 Alexion Pharmaceuticals shares in Q1 2019, an estimated $22K.
Claybrook Capital first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Claybrook Capital's Alexion Pharmaceuticals position peaked at $22K in Q4 2018.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.